文献速递临床试验与 GCP基础与转化研究

同种异体脂肪来源间充质基质细胞肌内注射治疗无法血运重建的糖尿病重症肢体缺血:随机双盲II期试验方案(NOMA试验)

Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial).
PubMed 文献 · Trials · 2021-09-06

主要结局为安全性(研究期间不良事件发生率),次要结局为临床、实验室和影像学疗效参数,第三结局为生活质量(SF-12和VascuQol-6量表)。

要点

  • 针对2型糖尿病合并重症肢体缺血且无法血运重建患者,评估脂肪来源间充质基质细胞肌内注射的可行性、安全性和疗效。
  • 主要结局为安全性(不良事件发生率),次要结局包括临床、实验室和影像学参数,第三结局为生活质量量表评分。

核心结论

  • 该试验旨在评估同种异体脂肪来源扩增间充质基质细胞肌内注射治疗2型糖尿病合并重症肢体缺血且无法血运重建患者的可行性、安全性和疗效。

研究设计与样本

  • 治疗为单次给药,患者随访12个月。

主要发现

  • 主要结局(安全性)通过研究期间不良事件发生率评估。
  • 次要结局(疗效)通过临床、实验室和影像学检查参数评估。
  • 第三结局(生活质量)采用SF-12和VascuQol-6量表评估。

关键数值与推荐

  • 纳入标准:2型糖尿病合并重症肢体缺血且无血运重建可能。
  • 分组:对照组(n=30)、低细胞剂量组(n=30)、高细胞剂量组(n=30),单次给药,随访12个月。
  • 主要结局指标:研究期间不良事件发生率。

临床怎么用

  • 若试验证实安全有效,脂肪来源间充质基质细胞肌内注射可能为无法血运重建的糖尿病重症肢体缺血患者提供新的治疗选择。
  • 当前标准药物治疗(抗血小板和他汀类)对改善疾病效果不足,细胞治疗诱导治疗性血管新生是 promising 的替代策略。

局限性

  • 本文为研究方案,尚未报告试验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic lower limb ischemia develops earlier and more frequently in patients with type 2 diabetes mellitus. Diabetes remains the main cause of lower-extremity non-traumatic amputations. Current medical treatment, based on antiplatelet therapy and statins, has demonstrated deficient improvement of the disease. In recent years, research has shown that it is possible to improve tissue perfusion through therapeutic angiogenesis. Both in animal models and humans, it has been shown that cell therapy can induce therapeutic angiogenesis, making mesenchymal stromal cell-based therapy one of the most promising therapeutic alternatives. The aim of this study is to evaluate the feasibility, safety, and efficacy of cell therapy based on mesenchymal stromal cells derived from adipose tissue intramuscular administration to patients with type 2 diabetes mellitus with critical limb ischemia and without possibility of revascularization. METHODS: A multicenter, randomized double-blind, placebo-controlled trial has been designed. Ninety eligible patients will be randomly assigned at a ratio 1:1:1 to one of the following: control group (n = 30), low-cell dose treatment group (n = 30), and high-cell dose treatment group (n = 30). Treatment will be administered in a single-dose way and patients will be followed for 12 months. Primary outcome (safety) will be evaluated by measuring the rate of adverse events within the study period. Secondary outcomes (efficacy) will be measured by assessing clinical, analytical, and imaging-test parameters. Tertiary outcome (quality of life) will be evaluated with SF-12 and VascuQol-6 scales. DISCUSSION: Chronic lower limb ischemia has limited therapeutic options and constitutes a public health problem in both developed and underdeveloped countries. Given that the current treatment is not established in daily clinical practice, it is essential to provide evidence-based data that allow taking a step forward in its clinical development. Also, the multidisciplinary coordination exercise needed to develop this clinical trial protocol will undoubtfully be useful to conduct academic clinical trials in the field of cell therapy in the near future. TRIAL REGISTRATION: ClinicalTrials.gov NCT04466007 . Registered on January 07, 2020. All items from the World Health Organization Trial Registration Data Set are included within the body of the protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Soria-Juan B, Garcia-Arranz M, Llanos Jiménez L, et al. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial). Trials. 2021. PMID: 34488845. doi:10.1186/s13063-021-05430-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。